85 related articles for article (PubMed ID: 36683825)
1. Pharmacological Strategies for Overcoming Multidrug Resistance to Chemotherapy.
Fedotcheva TA; Shimanovsky NL
Pharm Chem J; 2023; 56(10):1307-1313. PubMed ID: 36683825
[TBL] [Abstract][Full Text] [Related]
2. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy.
Gupta SK; Singh P; Ali V; Verma M
Oncol Rev; 2020 Jul; 14(2):448. PubMed ID: 32676170
[TBL] [Abstract][Full Text] [Related]
3. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.
Chen Z; Shi T; Zhang L; Zhu P; Deng M; Huang C; Hu T; Jiang L; Li J
Cancer Lett; 2016 Jan; 370(1):153-64. PubMed ID: 26499806
[TBL] [Abstract][Full Text] [Related]
4. Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.
Karthikeyan S; Hoti SL
Anticancer Agents Med Chem; 2015; 15(5):605-15. PubMed ID: 25584696
[TBL] [Abstract][Full Text] [Related]
5. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR).
Lee CH
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):43-52. PubMed ID: 14754411
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.
Dei S; Braconi L; Romanelli MN; Teodori E
Cancer Drug Resist; 2019; 2(3):710-743. PubMed ID: 35582565
[TBL] [Abstract][Full Text] [Related]
7. Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update.
Engle K; Kumar G
Eur J Med Chem; 2022 Sep; 239():114542. PubMed ID: 35751979
[TBL] [Abstract][Full Text] [Related]
8. Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways.
Yang C; Mai Z; Liu C; Yin S; Cai Y; Xia C
Molecules; 2022 May; 27(11):. PubMed ID: 35684449
[TBL] [Abstract][Full Text] [Related]
9. Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study.
Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Jaragh-Alhadad LA; Oraby HF; Elkaeed EB; Mekhemer GAH; Gabr GA; Shawky AM; Sidhom PA; Soliman MES; Moustafa MF; Paré PW; Hegazy MF
Molecules; 2022 May; 27(10):. PubMed ID: 35630581
[TBL] [Abstract][Full Text] [Related]
10. JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells.
Oh Y; Lee JS; Lee JS; Park JH; Kim HS; Yoon S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562984
[TBL] [Abstract][Full Text] [Related]
11. Co-treatment of Low Dose Pacritinib, a Phase III Jak2 Inhibitor, Greatly Increases Apoptosis of P-gp Over-expressing Cancer Cells With Multidrug Resistance.
Oh Y; Lee JS; Lee JS; Park JH; Kim HS; Yoon S
Anticancer Res; 2022 May; 42(5):2433-2442. PubMed ID: 35489775
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant Potential of Quercetin and its
Chen S; Tang Y; Gao Y; Nie K; Wang H; Su H; Wang Z; Lu F; Huang W; Dong H
Front Pharmacol; 2022; 13():865376. PubMed ID: 35462940
[TBL] [Abstract][Full Text] [Related]
13. Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells.
Boichuk S; Dunaev P; Mustafin I; Mani S; Syuzov K; Valeeva E; Bikinieva F; Galembikova A
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327403
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
